Clinical trial
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
NCT07280585 is registered in ClinicalTrials.gov with University of Cologne as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
- Lead sponsor
- University of Cologne
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 16, 2025
- Completion date
- May 15, 2030
- Enrollment
- 420 (estimated)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.